Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;15(2):E81-E90.
doi: 10.5489/cuaj.7074.

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)

Fred Saad  1 , Armen Aprikian  2 , Antonio Finelli  3 , Neil E Fleshner  3 , Martin Gleave  4 , Anil Kapoor  5 , Tamim Niazi  6 , Scott A North  7 , Frederic Pouliot  8 , Ricardo A Rendon  9 , Bobby Shayegan  5 , Srikala S Sridhar  10 , Alan So  4 , Nawaid Usmani  11 , Eric Vigneault  12 , Kim N Chi  13
Affiliations

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)

Fred Saad et al. Can Urol Assoc J. 2021 Feb.

Erratum in

  • Errata.
    [No authors listed] [No authors listed] Can Urol Assoc J. 2021 May;15(5):E304. doi: 10.5489/cuaj.7321. Can Urol Assoc J. 2021. PMID: 33939603 Free PMC article. No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Saad has been an advisory board member for and has received payment/honoraria from Abbvie, Amgen, Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Amgen, Astellas, Bayer, Janssen, and Sanofi. Dr. Aprikian has been an advisory board member for Abbvie, Astellas, and Bayer; and has received grants from Abbvie, Astellas Bayer, Sanofi, and TerSera. Dr. Finelli has been an advisory board member for Abbvie, Astellas, Bayer, Janssen, Ipsen, Sanofi, and TerSera; and has participated in clinical trials supported by Astellas, Bayer, and Janssen. Dr. Fleshner has been a consultant or advisory board member for Abbvie, Amgen, Astellas, Bayer, Ferring, Hybridyne Health, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Medivalion, Nucleix, Progenics Pharmaceutical, Sanofi, and Spectracure AB. Dr. Gleave has been a consultant for and has received honoraria/grants from Abbvie, Amgen, Astellas, Bayer, GDx, Janssen, MDX, Pfizer, and Sanofi; and is founder/holds a patent with OncoGenex. Dr. Kapoor has been an advisory board member for BMS, Eisai, Ipsen, Merck, Novartis, Pfizer, and Roche; a speakers’ bureau member for Eisai, Ipsen, Novartis, and Roche; and has received grants/honoraria from BMS, Eisai, Ipsen, Merck, Novartis, Pfizer, and Roche. Dr. Niazi has received research grants and honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Ferring, Janssen, and Sanofi. Dr. North has been an advisory board member for Astellas, has received honoraria from Astra Zeneca, Astellas, Janssen, Merck, Roche, and Sanofi; and has participated in clinical trials supported by Astra Zeneca, Merck, Roche, and Sanofi. Dr. Pouliot has been an advisory board member for Amgen, Astellas, Bayer, and Janssen; has received payment from Abbott, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Janssen, and Sanofi; has received grants from Astra Zeneca and Sanofi; and has participated in clinical trials supported by Astellas, Bayer, Ferring, and Janssen. Dr. Rendon has been an advisory board and speakers’ bureau member for and has received honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Jansen, and Sanofi. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Sridhar has been an advisory board member for Astellas, AstraZeneca, Bayer, Janssen, Merck, and Roche; and has participated in several pharma-supported clinical trials. Dr. So has been an advisory board member for Abbvie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Usmani has been an advisory board member for Amgen, Astellas, and Bayer; and has received grants from Best Medical and Concure Oncology Canada. Dr. Vigneault has been an advisory board member for Abbvie, Bayer, Ferring, and Sanofi. Dr. Chi has received honoraria from Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Astra Zeneca, Bayer, Eli Lilly, Essa, Janssen, Merck, Novartis, Pfizer, Roche, and Sanofi.

Figures

Fig. 1
Fig. 1
Management of castration-resistant prostate cancer (CRPC). m: months; mCRPC: metastatic CRPC; HRR: homologous recombination repair; PSADT: prostate-specific antigen doubling time.
See this image and copyright information in PMC

References

    1. Mohler JL, Gregory CW, Ford OH, 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440–8. doi: 10.1158/1078-0432.CCR-1146-03. - DOI - PubMed
    1. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59. doi: 10.1200/JCO.2007.12.4487. - DOI - PMC - PubMed
    1. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate non-metastatic prostate cancer. J Clin Oncol. 2005;23:2918–25. doi: 10.1200/JCO.2005.01.529. - DOI - PubMed
    1. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase 3 trial (CALGB 9583) J Clin Oncol. 2004;22:1025–33. doi: 10.1200/JCO.2004.06.037. - DOI - PubMed
    1. Smith MR, Saad F, Chowdhury S, et al. SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18. doi: 10.1056/NEJMoa1715546. - DOI - PubMed

LinkOut - more resources